Supernus Pharmaceuticals, Inc. (SUPN)

Supernus Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 6 analysts polled by S&P Global, Supernus Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $62.83. The average 1-year stock price forecast is 30.33% higher than the current stock price, while the lowest is $55 (+14.08%) and the highest is $66 (+36.90%).

Price Target: $62.83 (+30.33%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$55	$62.83	$64	$66
Change	+14.08%	+30.33%	+32.75%	+36.90%

* Price targets were last updated on Dec 19, 2025.

Analyst Ratings

The average analyst rating for Supernus Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	2	2	2	2	2	2
Buy	2	2	2	2	2	2
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	5	5	5	5	5	5

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Annabel Samimy Stifel	Stifel	Hold Maintains $50 → $55	Hold	Maintains	$50 → $55	+14.08%	Dec 19, 2025
Pavan Patel B of A Securities	B of A Securities	Strong Buy Initiates $65	Strong Buy	Initiates	$65	+34.83%	Oct 29, 2025
Stacy Ku TD Cowen	TD Cowen	Strong Buy Maintains $45 → $60	Strong Buy	Maintains	$45 → $60	+24.46%	Oct 23, 2025
David Amsellem Piper Sandler	Piper Sandler	Hold → Buy Upgrades $40 → $65	Hold → Buy	Upgrades	$40 → $65	+34.83%	Oct 9, 2025
Kristen Kluska Cantor Fitzgerald	Cantor Fitzgerald	Buy Maintains $46 → $63	Buy	Maintains	$46 → $63	+30.68%	Sep 30, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

883.54M

Increased by 22.89%

from 718.95M

Revenue Next Year

1.04B

Increased by 17.26%

from 883.54M

EPS This Year

2.20

from -0.68

EPS Next Year

4.05

Increased by 84.08%

from 2.20

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	579.78M	667.24M	607.52M	661.82M	718.95M	883.54M	1.04B
Revenue Growth	11.41%	15.09%	-8.95%	8.94%	8.63%	22.89%	17.26%
EPS	0.98	1.04	0.02	1.32	-0.68	2.20	4.05
EPS Growth	-58.48%	6.32%	-98.08%	6,500.00%	-	-	84.08%
Forward PE	-	-	-	-	-	21.92	11.91
No. Analysts	-	-	-	-	-	8	8

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027	2028	2029	2030	2031	2032	2033
High	914.3M	1.1B
Avg	883.5M	1.0B
Low	841.8M	976.4M

Revenue Growth

Revenue Growth	2026	2027	2028	2029	2030	2031	2032	2033
High	27.2%	23.1%
Avg	22.9%	17.3%
Low	17.1%	10.5%

EPS Forecast

EPS	2026	2027	2028	2029	2030	2031	2032	2033
High	3.10	5.00
Avg	2.20	4.05
Low	1.10	2.60

EPS Growth

EPS Growth	2026	2027	2028	2029	2030	2031	2032	2033
High	-	127.2%
Avg	-	84.1%
Low	-	18.1%

Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.